Inclisiran, novel cholesterol lowering siRNA is effective in reducing LDL cholesterol by >50% safely, as per the results published by ORION-10 phase III study.
Inclisiran, a novel cholesterol lowering siRNA which inhibits the production of PCSK9 in hepatocytes have shown to be effective in reducing LDL-C cholesterol by >50% as per the results presented on Saturday at American Heart Association scientific sessions 2019 at Philadelphia.